Chronisch-entzündliche Erkrankungen (CEDs)

GO-OBSERVE

Europäische prospektive Beobachtungsstudie zum subjektiv (vom Patienten) beurteilten kontinuierlichen klinischen Ansprechen auf SIMPONI bei Erwachsenen mit moderater bis schwerer aktiver Colitis ulcerosa

Anprechpartner: Dr. A. Schirbel, Dr. U.-F. Pape

GA28950 - ETROLIZUMAB

Phase III, double blind, placebo-controlled, multicenter study of the efficacy and safety of Etrolizumab during induction and maintenance in patients with moderate to severe active Ulcerative Colitis who are refractory to or intolerant of TNF inhibitors

Anprechpartner: Dr. A. Schirbel, Dr. U.-F. Pape, Dr. A. Fischer

GA29102 - ETROLIZUMAB VERSUS PLACEBO

Phase III, randomized, double blind, placebo-controlled, multicenter study to evaluate the efficacy (maintenance of remission) and safety of Etrolizumab compared with placebo in patients with moderate to severe active Ulcerative Colitis who are naive to TNF inhibitors

Anprechpartner: Dr. A. Schirbel, Dr. U.-F. Pape, Dr. A. Fischer

Abbvie M14-033 - Adalimumab Hochdosis-Studie bei M. Crohn

A Multicenter, Randomized, Double-Blind Study to Evaluate Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration

Anprechpartner: Dr. A. Fischer

EARNEST - Vedolizumab bei chronischer Pouchitis

A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis

Anprechpartner: Dr. A. Fischer

GA29144 - Etrolizumab bei M. Crohn

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction And Maintenance Treatment For Patients With Moderately to Severely Active Crohn's Disease

Anprechpartner: Dr. A. Fischer

GS-US-419-3895 - Filgotinib bei M. Crohn

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Crohn's Disease

Anprechpartner: Dr. A. Fischer

SELECTION1 - Filgotinib bei Colitis ulcerosa

Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Ulcerative Colitis

Anprechpartner: Dr. A. Fischer

MLN0002SC-3030 - Vedolizumab Subkutanstudie

A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn's Disease

Anprechpartner: Dr. A. Fischer

MLN0002SC-3031 - Vedolizumab Subkutanstudie

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy

Anprechpartner: Dr. A. Fischer

RPC01-3101 - Ozanimod bei Colitis ulcerosa

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis

Anprechpartner: Dr. A. Fischer

STARDUST - Ustekinumab-Dosisstudie bei M. Crohn

Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab

Anprechpartner: Dr. A. Fischer

TRIDENT - JNJ-64304500 bei M. Crohn

A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter protocol to evaluate the safety and efficacy of JNJ-64304500 in subjects with moderately to severely active Crohn's disease

Anprechpartner: Dr. A. Fischer